Program
enlonstobart
Also written as “SG001”, “Enlonstobart” and “SYS6041, enlonstobart, bevacizumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Stomach Neoplasms · Uterine Cervical Neoplasms · Ovarian Neoplasms, led by 2 companies.
Drug pageEnlonstobart: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 1410 open or running | phase 3since Jan 16, 2023 | Feb 20, 2019 | Apr 2027phase 2 · NCT06136988 |
| Shanghai Runshi Pharmaceutical Technology | 11 open or running | phase 2since Nov 9, 2023 | Nov 9, 2023 | Jan 30, 2027phase 2 · NCT06132217 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Runshi Pharmaceutical Technology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 19, 2023Named enlonstobartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, SG001
- Nov 9, 2023First study: phase 2 study in Advanced Solid TumorFirst studyNCT06132217 · 168 planned · China
Ahead
- Jan 30, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06132217
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
The one study Shanghai Runshi Pharmaceutical Technology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06132217Advanced Solid Tumor · China | 2 | Not yet recruiting | Jan 30, 2027 | 168 |
How it is read
Names in the registry
- “SG001”, 8 entries
- “Enlonstobart”, 3 entries
- “SYS6041, enlonstobart, bevacizumab”, 1 entry
- “Enlonstobart injection”, 1 entry
- “SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
- Stomach Neoplasms, 2 studies
- Uterine Cervical Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.